FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074202192> ?p ?o ?g. }

• W2074202192 endingPage "e38853" @default.
• W2074202192 startingPage "e38853" @default.
• W2074202192 abstract "Background Humanized mice generate a lymphoid system of human origin subsequent to transplantation of human CD34+ cells and thus are highly susceptible to HIV infection. Here we examined the efficacy of antiretroviral treatment (ART) when added to food pellets, and of long-acting (LA) antiretroviral compounds, either as monotherapy or in combination. These studies shall be inspiring for establishing a gold standard of ART, which is easy to administer and well supported by the mice, and for subsequent studies such as latency. Furthermore, they should disclose whether viral breakthrough and emergence of resistance occurs similar as in HIV-infected patients when ART is insufficient. Methods/Principal Findings NOD/shi-scid/γcnull (NOG) mice were used in all experimentations. We first performed pharmacokinetic studies of the drugs used, either added to food pellets (AZT, TDF, 3TC, RTV) or in a LA formulation that permitted once weekly subcutaneous administration (TMC278: non-nucleoside reverse transcriptase inhibitor, TMC181: protease inhibitor). A combination of 3TC, TDF and TMC278-LA or 3TC, TDF, TMC278-LA and TMC181-LA suppressed the viral load to undetectable levels in 15/19 (79%) and 14/14 (100%) mice, respectively. In successfully treated mice, subsequent monotherapy with TMC278-LA resulted in viral breakthrough; in contrast, the two LA compounds together prevented viral breakthrough. Resistance mutations matched the mutations most commonly observed in HIV patients failing therapy. Importantly, viral rebound after interruption of ART, presence of HIV DNA in successfully treated mice and in vitro reactivation of early HIV transcripts point to an existing latent HIV reservoir. Conclusions/Significance This report is a unique description of multiple aspects of HIV infection in humanized mice that comprised efficacy testing of various treatment regimens, including LA compounds, resistance mutation analysis as well as viral rebound after treatment interruption. Humanized mice will be highly valuable for exploring the antiviral potency of new compounds or compounds targeting the latent HIV reservoir." @default.
• W2074202192 created "2016-06-24" @default.
• W2074202192 creator A5002266122 @default.
• W2074202192 creator A5007273003 @default.
• W2074202192 creator A5018395563 @default.
• W2074202192 creator A5018779197 @default.
• W2074202192 creator A5019595634 @default.
• W2074202192 creator A5026680112 @default.
• W2074202192 creator A5043552483 @default.
• W2074202192 creator A5049875164 @default.
• W2074202192 creator A5052576334 @default.
• W2074202192 creator A5056310027 @default.
• W2074202192 creator A5062667602 @default.
• W2074202192 creator A5064101498 @default.
• W2074202192 creator A5071404062 @default.
• W2074202192 creator A5076422838 @default.
• W2074202192 creator A5080704951 @default.
• W2074202192 creator A5088486375 @default.
• W2074202192 date "2012-06-13" @default.
• W2074202192 modified "2023-09-27" @default.
• W2074202192 title "Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1" @default.
• W2074202192 cites W1969379511 @default.
• W2074202192 cites W1982781171 @default.
• W2074202192 cites W1985067585 @default.
• W2074202192 cites W1986296710 @default.
• W2074202192 cites W1990750190 @default.
• W2074202192 cites W1997371346 @default.
• W2074202192 cites W2007243618 @default.
• W2074202192 cites W2009424749 @default.
• W2074202192 cites W2010519150 @default.
• W2074202192 cites W2011560351 @default.
• W2074202192 cites W2013590197 @default.
• W2074202192 cites W2013769454 @default.
• W2074202192 cites W2046677139 @default.
• W2074202192 cites W2056413661 @default.
• W2074202192 cites W2056424254 @default.
• W2074202192 cites W2073377580 @default.
• W2074202192 cites W2073489229 @default.
• W2074202192 cites W2079573278 @default.
• W2074202192 cites W2080343277 @default.
• W2074202192 cites W2084686975 @default.
• W2074202192 cites W2092029464 @default.
• W2074202192 cites W2099826019 @default.
• W2074202192 cites W2106408660 @default.
• W2074202192 cites W2111220127 @default.
• W2074202192 cites W2121836743 @default.
• W2074202192 cites W2125962158 @default.
• W2074202192 cites W2134663557 @default.
• W2074202192 cites W2134960674 @default.
• W2074202192 cites W2136683144 @default.
• W2074202192 cites W2137255891 @default.
• W2074202192 cites W2137906256 @default.
• W2074202192 cites W2142538462 @default.
• W2074202192 cites W2144373564 @default.
• W2074202192 cites W2155464620 @default.
• W2074202192 cites W2156212256 @default.
• W2074202192 cites W2159992227 @default.
• W2074202192 cites W2317264403 @default.
• W2074202192 cites W2332089235 @default.
• W2074202192 cites W3043125680 @default.
• W2074202192 doi "https://doi.org/10.1371/journal.pone.0038853" @default.
• W2074202192 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3374767" @default.
• W2074202192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22719966" @default.
• W2074202192 hasPublicationYear "2012" @default.
• W2074202192 type Work @default.
• W2074202192 sameAs 2074202192 @default.
• W2074202192 citedByCount "70" @default.
• W2074202192 countsByYear W20742021922012 @default.
• W2074202192 countsByYear W20742021922013 @default.
• W2074202192 countsByYear W20742021922014 @default.
• W2074202192 countsByYear W20742021922015 @default.
• W2074202192 countsByYear W20742021922016 @default.
• W2074202192 countsByYear W20742021922017 @default.
• W2074202192 countsByYear W20742021922018 @default.
• W2074202192 countsByYear W20742021922019 @default.
• W2074202192 countsByYear W20742021922020 @default.
• W2074202192 countsByYear W20742021922021 @default.
• W2074202192 countsByYear W20742021922022 @default.
• W2074202192 countsByYear W20742021922023 @default.
• W2074202192 crossrefType "journal-article" @default.
• W2074202192 hasAuthorship W2074202192A5002266122 @default.
• W2074202192 hasAuthorship W2074202192A5007273003 @default.
• W2074202192 hasAuthorship W2074202192A5018395563 @default.
• W2074202192 hasAuthorship W2074202192A5018779197 @default.
• W2074202192 hasAuthorship W2074202192A5019595634 @default.
• W2074202192 hasAuthorship W2074202192A5026680112 @default.
• W2074202192 hasAuthorship W2074202192A5043552483 @default.
• W2074202192 hasAuthorship W2074202192A5049875164 @default.
• W2074202192 hasAuthorship W2074202192A5052576334 @default.
• W2074202192 hasAuthorship W2074202192A5056310027 @default.
• W2074202192 hasAuthorship W2074202192A5062667602 @default.
• W2074202192 hasAuthorship W2074202192A5064101498 @default.
• W2074202192 hasAuthorship W2074202192A5071404062 @default.
• W2074202192 hasAuthorship W2074202192A5076422838 @default.
• W2074202192 hasAuthorship W2074202192A5080704951 @default.
• W2074202192 hasAuthorship W2074202192A5088486375 @default.
• W2074202192 hasBestOaLocation W20742021921 @default.
• W2074202192 hasConcept C104317684 @default.

• next